B
Bayer
Bayer is a Series A to Series D stage investment firm. It has made 17 investments. 35% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $87.2M (across 16 rounds with reported amounts).
Portfolio
17
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
20 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| LLeaf | Series B | $13M | Jan 2026 |
 Understory | Series A | — | Sep 2025 |
 eGenesis | Series D | $191M | Aug 2025 |
 Transcarent | Series D | $126M | May 2024 |
 one.bio | Series A | $27M | Jan 2024 |
| Transcarent | Series D | $126M | Jan 2024 |
 Transcarent | Series D | $126M | Jan 2024 |
 Capstan | Series A | $102M | Sep 2022 |
 Cellino | Series A | $75M | Jan 2022 |
 Capstan Therapeutics | Series A | $102M | Jan 2022 |
| GGuardian Ag | Unknown | $10.5M | Apr 2021 |
 CoverCress Inc. | Unknown | $8M | Mar 2021 |
 Senti Bio | Series B | — | Jan 2021 |
 Andes | Series A | $15M | Jan 2021 |
| UUnfold | Series B | — | Aug 2020 |
| CoverCress Inc. | Series A | $2M | Apr 2020 |
| OOerth Bio | Unknown | $55M | Jan 2019 |
| Cellino | Series C | $80M | — |
 Immunitas Therapeutics | Seed | — | — |
 CRISPR Therapeutics | Unknown | $337M | — |
Top Co-Investors
Leaps by Bayer11 shared
Khosla Ventures3 shared
General Catalyst3 shared
Memorial Hermann Health System3 shared
Alexandria Venture Investments3 shared
Polaris Partners3 shared
Prelude Ventures3 shared
Alta Partners3 shared
8VC2 shared
Humboldt Fund2 shared
The Engine2 shared
Felicis2 shared
Bristol Myers Squibb2 shared
Pfizer Ventures2 shared
Eli Lilly and Company2 shared
Geodesic Capital2 shared
Human Ventures2 shared
Threshold Ventures2 shared
Ally Bridge Group2 shared
Last updated: 20 October 2026